Menzies NA

Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries – a model-based cost-effectiveness analysis
Marx FM, Hauer B, Menzies NA, Haas W, Perumal N

BMC Public Health

(2021)

https://doi.org/10.1186/s12889-021-12142-4
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G

The Lancet Global Health

(2020)

https://doi.org/10.1016/S2214-109X(20)30227-8
Post-tuberculosis mortality and morbidity: valuing the hidden epidemic
Quaife M, Houben RMJ, Allwood BW, Cohen T, Coussens AK, Harries AD, Marx FM, Sweeney S, Wallis RS, Menzies NA

The Lancet Respiratory Medicine

(2020)

https://doi.org/10.1016/S2213-2600(20)30039-4
Using modeling to inform international guidelines for antiretroviral treatment
Hallett TB, Keebler D, Revill P, Menzies NA, Bórquez A, McRobie E, Eaton JW

AIDS

(2014)

https://doi.org/10.1097/QAD.0000000000000115
Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models
Walker S, Blaser N, Easterbrook P, Borquez A, Doherty M, Cambiano V, Hirnschall G, Welte A, Ciaranello A, Keiser O, Estill J, Hallett TB, Hill A, Gray R, Kessler J, Keebler D, Menzies NA, Revill P, Nucifora KA, Braithwaite S, Vizcaya LS, Phillips AN

The Lancet Global Health

(2014)

https://doi.org/10.1016/S2214-109X(13)70048-2